retatrutide clinical trials safety efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide is getting attention —

The two drugs may share a pharmacological category, but their safety profiles are not equivalent

The statutory framework for compounding has always been limited, and as supply and access to approved products evolve, so too does the Agencys enforcement posture

Through telehealth at DevotedDOc , patients can now access GLP-1 prescriptions without the need for frequent in-person visits

367 The administration of liraglutide also impeded osteoclastic bone formation, thereby inhibiting bone resorption and exerting protective effects on bone health in T1D mice

Monitor closely: Weight, appetite, sideeffects, and bloodwork

If you havent lost at least 5% body weight by week 12, discuss dose escalation with your physician